-4.5%
AKAM vs GSK
+47.2%
-51.7%
-46.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.3% | 0.0% | -0.3% | -0.3% |
| 7D | +1.5% | -3.5% | +5.0% | +2.0% |
| 30D | -13.0% | -3.4% | -9.6% | -12.6% |
| 3M | -19.4% | -8.1% | -11.3% | -18.5% |
| 6M | +0.3% | -11.1% | +11.4% | +1.8% |
| YTD | +22.4% | +0.7% | +21.7% | +20.5% |
| 1Y | +34.8% | +20.1% | +14.7% | +26.9% |
| 3Y | +1.9% | +46.1% | -44.2% | -9.9% |
| All | -4.5% | +47.2% | -51.7% | -16.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling